Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial

•The ORR to palbociclib + cetuximab in cetuximab-resistant HPV-related OPSCC was 4%.•Stable disease with ≥ 10% decrease in target lesions occurred in 8%.•The median PFS was 1.9 months and the median OS was 17.1 months.•Grade 3–4 palbociclib-related AEs, mostly non-febrile leukopenia, occurred in 46%...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oral oncology 2021-03, Vol.114, p.105164-105164, Article 105164
Hauptverfasser:	Oppelt, Peter, Ley, Jessica C., Worden, Francis, Palka, Kevin, Maggiore, Ronald, Liu, Jingxia, Adkins, Douglas
Format:	Artikel
Sprache:	eng
Schlagworte:	Cetuximab Head and neck cancer Human papillomavirus Palbociclib Squamous-cell carcinoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!